The 4 most recent market catalysts affecting $ALGS, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 12, 2026
Corporate Catalyst
Bullish
Impact 60
Aligos Therapeutics Initiates Dosing In Phase 1 Study Of ALG-170675, Investigational Next-Gen Antisense Oligonucleotide Being Evaluated For Functional Cure In Treatment Of Chronic HBV Infection
Aligos Therapeutics has initiated dosing in a Phase 1 study for ALG-170675, an investigational antisense oligonucleotide for chronic HBV infection. This is a positive development f…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 75
Aligos Therapeutics shares are trading higher after the company reported better-than-expected Q2 earnings results.
This headline indicates a strong positive corporate catalyst for Aligos Therapeutics (ALGS). Better-than-expected earnings often signal robust financial health, effective managemen…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 92
Aligos Therapeutics Q2 EPS $(0.14) Beats $(1.07) Estimate, Sales $0.000 Miss $18.243M Estimate
Aligos Therapeutics announced Q2 earnings where their loss per share was significantly better than analyst estimates, suggesting effective cost management. However, the company rep…
Jul 13, 2026
Corporate Catalyst
Bullish
Impact 65
Aligos Therapeutics Completes Enrollment Of HBeAg+ Patients In Its Phase 2 B-SUPREME Trial Of Pevifoscorvir Sodium To Treat Chronic Hepatitis B Virus Infection
Aligos Therapeutics has completed enrollment for its Phase 2 B-SUPREME trial, a significant step in the development of pevifoscorvir sodium for chronic hepatitis B. This matters be…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.